Serzone
(Nefazodone)Phase 3Small molecule
Bristol-Myers SquibbSerzone is one of 65 small molecule programs targeting Cocaine Abuse. It is currently in Phase 3.
2
Indications
5
Total Trials
0
Active Trials
64
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
101 competitors in Cocaine Dependence
#DrugCompanyPhaseTrials
1Permax
VValeant Pharmaceuticals
Phase 3
Bupropion XL
GSKPhase 3
Celexa
AbbViePhase 2
Ritalin
NovartisPhase 2
Buspar
Bristol-Myers SquibbPhase 2
Tegretol
NovartisPhase 2
Dostinex
PfizerPhase 2
Sabril
LundbeckPhase 2
Revia
TevaPhase 2
Zofran
NovartisPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cocaine Abuse2 trials
Effectiveness1 trial
Cocaine Dependence1 trial
Nefazodone in the Treatment of Cocaine Dependence and Depression - 4
Completed·—·Phase 2·NCT00015210·69 enrolled
Regulatory
FDA Approval Timeline[4]
Dec 22, 1994
SERZONE
NDA NDA020152
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nefazodone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company